Amos Katz

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.1K citations · Full text

Cardiomyopathy, Structural Heart Disease, Cardiovascular Disease +2

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Sonia S. Anand, Jackie Bosch, John W. Eikelboom et al. · The Lancet · 2017 · 855 citations · Full text

Thrombosis, Cardiovascular Disease, Stroke +13

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Stuart J. Connolly, John W. Eikelboom, Jackie Bosch et al. · The Lancet · 2017 · 749 citations · Full text

Thrombosis, Cardiovascular Disease, Atherosclerosis +12

Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial

Gerhard Hindricks, Miloš Táborský, Michael Glikson et al. · The Lancet · 2014 · 719 citations

Heart Failure, Engineering, Device Therapy +13